Background Bradykinin, a nonapeptide that contributes as a mediator to the pathogenesis of asthma, may affect lung mucociliary clearance, as it has been shown to be a potent secretagogue in canine airways and in human nasal mucosa in vivo. To evaluate this possibility the effect ofinhaled bradykinin on mucociliary clearance has been studied in 10 healthy volunteers. Methods Subjects attended the laboratory on two occasions to take part in tracheobronchial clearance studies using a non-invasive radioisotopic technique. Inhalation of radioaerosol was followed 30 minutes later by inhalation of either bradykinin (8 mgiml) or vehicle placebo in a randomised, double blind fashion. After each inhalation the number of coughs was recorded. Whole lung radioactivity was measured every half hour for six hours with two collimated scintillation counters, and a tracheobronchial clearance curve was plotted for each subject on each occasion. Results Mucociliary clearance, expressed as the area under the tracheobronchial radioaerosol retention curve calculated for the first six hours (AUCQ6h), was greater in nine out of 10 subjects after inhalation of bradykinin than after placebo. The (Thorax 1992;47:952-956) Bradykinin is a nonapeptide that may be an important mediator in the pathogenesis of airway inflammation by interacting with specific receptors, mainly of the B2 type.' -The observation that kinin like activity is recovered in increased amounts from lavage fluid following provocation by allergen of the nasal4 and bronchial mucosa5 of atopic subjects indicates that this pathway is activated in human allergic disease. Inhaled bradykinin elicits many of the features of asthma, including bronchoconstriction," cough,7 plasma exudation,910 and mucus secretion. 
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The impairment of mucociliary function, which has been recently found in patients with both symptomatic and asymptomatic asthma,12 13 may be related to local release of chemical mediators of anaphylaxis, including bradykinin. In support of this, it has been reported that the allergen provoked early asthmatic reaction is accompanied by a decrease in tracheal mucus transport in asthmatic patients, which could be reversed by pretreatment with sodium cromoglycate,"'5 a drug that has a potent inhibitory activity on bradykinin responses in the airways. 7 Animal and in vitro studies suggest that bradykinin may have various effects on different components of the mucociliary transport system. Bradykinin may be directly responsible for the impaired mucociliary clearance in asthma as it has been shown to be a potent mucus secretagogue in canine airways in vivo" and in human nasal mucosa in vitro.'6 It also stimulates chloride secretion by canine airway epithelial cells,'7 leading to an increase in the water content within the periciliary fluid. Altered mucus transport may result not only from abnormalities of the rheological properties of airway secretions but also from impairment of ciliary function. Recently Tamaoki et all8 have shown that bradykinin stimulates ciliary motility in isolated rabbit tracheal epithelium. From these studies an alteration in mucociliary clearance by bradykinin could be predicted.
To our knowledge the effect of bradykinin on bronchial mucociliary clearance in man has not been previously studied. Owing to the complexity of studying the mucociliary clearance response to inhaled bradykinin in asthmatic subjects because of its potent bronchoconstrictor effect,6'8 we decided to investigate the effect of inhaled bradykinin on mucociliary clearance using a radioaerosol technique in a group of healthy volunteers.
SUBJECTS
Ten healthy subjects (eight of them male), ranging in age from 19 before radioaerosol inhalation or in the subsequent 24 hours' observation period. They took no medication and were free from respiratory tract infections for at least four weeks before and throughout the investigation.
Subjects were allowed a light breakfast on the day of the study but could not have caffeine containing substances for the previous 12 hours. hours to estimate radioaerosol deposition on non-ciliated airways ("alveolar deposition"). To overcome unavoidable differences in the amount of radioactivity initially measured in the lung, all counts were expressed as a percentage of the initial count after correction for the natural decay of the radioisotope and background radioactivity. Alveolar deposition for each subject was expressed as the percentage of the initial lung activity remaining in the lungs at 24 hours and was subtracted from all readings of the whole lung clearance curve to give a tracheobronchial clearance curve. Throughout the first six hours after radioaerosol inhalation all coughs were recorded.
BRADYKININ ADMINISTRATION
On each occasion bradykinin triacetic acid (Nova Biochem Ltd, Nottingham) was freshly prepared in 10% ethanol in normal saline to produce 3 ml of solution containing 24 mg. To avoid loss of bradykinin through adherence to plastic surfaces and oxidation, the solution was kept stored at 4'C before use and administered within 20 minutes of reconstitution. The control vehicle solution (placebo) consisted of the 10% ethanol-saline diluent used for dissolving the bradykinin. Both the placebo and the bradykinin solutions were administered as aerosols generated from a starting volume of 3 ml in a disposable Inspiron Mini +Median (range).
FVC-forced vital capacity; PEF-peak expiratory flow.
randomised and double blind manner. The inhalation procedure with both bradykinin and vehicle placebo was repeated on a further three occasions at half hourly intervals. After each inhalation of bradykinin and placebo solutions, the number of coughs was counted and recorded by an independent observer. Although subjects were not told which was the active solution, the pharyngeal irritation with bradykinin made it difficult to maintain blindness. The investigators responsible for analysing the data (AH and DP) were not, however, aware of the subjective sensations of the subjects studied, who were blind to the rationale of the study. Regular whole lung counts were obtained as described above and a tracheobronchial clearance curve was plotted for each subject on each occasion. 
Results
There were no significant differences in the baseline spirometric values between the two study days (table 2) . Similarly, inspiratory flow rates, penetration indices, and alveolar depositions were not significantly different on bradykinin and placebo study days (table 2) . All subjects noticed pharyngeal irritation after inhaling bradykinin; this was most noticeable with the first inhalation but rapidly diminished during subsequent inhalations. In addition, four subjects (subjects 7, 8, 9, 10) had a dry cough with bradykinin. Although the median (range) number of coughs recorded after bradykinin inhalations (2-0 (0-18)) was significantly higher than the 0 5 (0-2) after placebo (p < 0-05), no significant correlation was found between acceleration of tracheobronchial clearance and number of coughs recorded throughout the first six hours after radioaerosol inhalation.
Mucociliary clearance, expressed as AUCO 6h and AUCO3h, was greater in nine out of 10 subjects after inhalation of bradykinin than after placebo (figure) 
Discussion
In the present study we have shown that repeated inhalations of bradykinin greatly enhance tracheobronchial clearance in normal human airways. Because the deposition pattern of the inhaled radioaerosol was the same on the two study days, as clearly shown by the reproducibility of penetration indices and alveolar deposition values, the speeding of mucociliary clearance is likely to indicate the true result of bradykinin stimulation and not different deposition of the radioaerosol on the two study days. With the nebulisation procedure used, about 10% of the dose administered to the mouth (80 ,ug) would be delivered to the airways of our subjects. This dose produces a concentration of the same magnitude as the concentration ofkinin like activity in bronchoalveolar lavage fluid from subjects with asthma,523 indicating that bradykinin released into the airways as a component of the inflammatory response in asthma might serve to influence the mucociliary transport.
The tracheobronchial retention curves in our subjects closely resemble those previously reported in normal human subjects. 24 The low concentration of alcohol used in the vehicle solution is therefore unlikely to have altered clearance as such. The technique of measuring tracheobronchial clearance used in this study is highly repeatable, with an intersubject coefficient ofvariation for healthy non-smokers of 13%, the intrasubject coefficient being half of the intersubject coefficient. 24 In view of the profound effects on mucosal inflammation"' and mucus hypersecretion16 6 reported in several studies performed-on animal models in vitro and in vivo after exposure to bradykinin, it is not surprising that this nonapeptide has a potent action on mucociliary clearance in human airways. That bradykinin may have indirect effects on mucociliary clearance is a possibility that remains to be investigated.
As healthy volunteers were studied in the present investigation, it is difficult to extrapolate these data to patients with bronchial asthma, whose clearance rate is already reduced.2 " Nevertheless, although the airways response to inhaled bradykinin differs strikingly in asthmatic and non-asthmatic subjects,68 mucociliary clearance may not differ in the same way. Indeed, histamine, another well known mediator of bronchoconstriction in asthma, when inhaled enhanced the mucociliary transport to a similar degree in healthy volunteers and in asthmatic subjects." 40 Mucociliary clearance has been reported to be slower in subjects with asthma, even during clinical remission, than in normal subjects.'2"5
These findings are at variance with the results of the present study, which show a speeding of the mucociliary clearance by acute exposure to bradykinin, a putative mediator in the pathophysiology of asthma. It has been recently reported, however, that acute exacerbations of asthma sharply accelerated mucociliary transport from baseline in eight asthmatic patients, even though two weeks after an asthma attack their mucociliary clearance was significantly less than the baseline level.4' Acute exposure to bradykinin may initially cause a transient increase in mucociliary function, whereas chronic exposure to this kinin may be followed by prolonged depression of mucociliary transport.
Although our findings clearly indicate that inhaled bradykinin stimulates tracheobronchial clearance in normal human airways, further experiments are required to confirm whether it is directly responsible for the impaired mucociliary transport seen in bronchial asthma. Only when suitable antagonists become available will it be possible to establish the importance of this mediator in modulating mucociliary transport.
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